View Post

Talazoparib Is Active in gBRCA1/2 Mutation-Positive, HER2-Negative Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Walter Alexander From: cancertherapyadvisor.com Neoadjuvant talazoparib demonstrated activity and pathologic complete response (pCR) rates comparable to those observed with combination anthracycline and taxane-based chemotherapy regimens in a phase 2 trial of patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, HER2-negative early breast cancer. The results were presented by Jennifer Keating Litton, MD, of The University of Texas MD Anderson Cancer Center …

View Post

Updated recommendations for managing hereditary breast cancer

In Clinical Studies News by Barbara Jacoby

Source: Health Day From: medicalxpress.com One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, according to a rapid recommendation update published by the American Society for Clinical Oncology (ASCO). Following presentation of the results from …

View Post

Refining Personalized Breast Cancer Risk Assessment

In Clinical Studies News by Barbara Jacoby

By: Greg Laub From: medpagetoday.com Holly Pederson explains how ancestry recalibrates polygenic risk score for better accuracy Polygenic risk scores (PRS), which can help determine breast cancer risk in patients, have primarily been developed and validated for populations of European descent. To make a PRS more accurate, researchers developed and validated a novel global PRS that utilizes individual ancestral genetic …

View Post

Most Women With Metastatic Breast Cancer Have Troubling Treatment Side Effects, Willing To Discuss Dosing Options With Doctor

In In The News by Barbara Jacoby

By: Jamie DePolo From: breastcancer.org About 86% of women diagnosed with metastatic breast cancer had at least one bad treatment-related side effect, and 92% were willing to discuss options for different dosing levels of medicines based on their unique situations, according to a study. The research was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. About …

View Post

Investigators: Same-Day Pegfilgrastim Is Safe and Effective in Patients Receiving CTX for Breast, Lung Cancer

In Clinical Studies News by Barbara Jacoby

By: Tony Hagen From: centerforbiosimilars.com Same-day pegfilgrastim to combat febrile neutropenia in conjunction with myelosuppressive chemotherapy (CTX) is safe, investigators conclude. Same-day vs next-day administration of pegfilgrastim as prophylaxis against febrile neutropenia (FN) in patients undergoing myelosuppressive chemotherapy (CTX) shows promise despite preexisting concerns this may increase the incidence of FN, investigators reported in studies of patients with lung and …

View Post

De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype

In Clinical Studies News by Barbara Jacoby

By: Ryan Lawrence From: healio.com A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer. Researchers presented the first survival data from the randomized, phase 2 WSG-ADAPT-HR-/HER2+ trial — part of the ADAPT umbrella protocol — during the virtual ASCO Annual …

View Post

Agendia test spots ultralow breast cancer recurrence risks, flagging women who could skip chemo

In Clinical Studies News by Barbara Jacoby

By: Conor Hale From: fiercebiotech.com Breast cancer test maker Agendia has delivered new data showing its MammaPrint genomic diagnostic can help identify patients at an ultralow risk of recurrence, including some who are likely to keep cancer at bay for at least 20 years. This information, culled from an analysis of 70 different genes, could help oncologists tailor treatment plans …

View Post

Sacituzumab Govitecan for Metastatic TNBC Retains Survival Advantage Over Chemotherapy

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: cancernetwork.com Patients with metastatic TNBC treated with sacituzumab govitecan maintained an efficacy benefit compared with physician’s choice chemotherapy. Patients with metastatic triple-negative breast cancer (TNBC) treated with sacituzumab govitecan (Trodelvy), an antibody-drug conjugate (ADC), maintained a benefit in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) compared with physician’s choice of therapy, regardless …

View Post

Research From Roswell Park and Kaiser Permanente Supports Vitamin D Supplementation for Breast Cancer Patients

In In The News by Barbara Jacoby

Source: Roswell Park From: roswellpark.org Benefits may be most pronounced for Black women and patients diagnosed with higher-stage disease The joint Roswell Park Comprehensive Cancer Center/Kaiser Permanente Northern California team behind a new study to be highlighted at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting has found that sufficient vitamin D levels at the time of …

View Post

Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

In Clinical Studies News by Barbara Jacoby

From: businesswire.com Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society …